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Summary
field of metastatic renal cell cancer (mrcc) treatments is now evolving at a rapid and unprecedented pace. nivolum-
ab prolongs survival in patients with metastatic kidney cancer with a favorable safety profile as demonstrated in the Check-
Mate 025 clinical trial. nivolumab compared to everolimus prolonged survival in patients with mrcc while 
exibiting favorbale safety profile. in this study we present the results of nivolumab treatment in patients with mrcc 
within named patient program (npp) at UHc Zagreb. in 30% of included patients survival was longer than 30 months and 
16.6% patients had a complete response.
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REZULTATI LIJEČENJA BOLESNIKA S METASTATSKIM RAKOM BUBREGA NIVOLUMABOM  
– DONACIJSKIM PROGRAMOM NA IME BOLESNIKA (NPP) U KLINIČKOM BOLNIČKOM CENTRU ZAGREB
Sažetak
Područje liječenja metastatskog raka bubrega (mRCC) je područje ubrzanog razvoja terapijskih mogućnosti. Nivolu-
mab produljuje preživljenje bolesnika s metastatskim rakom bubrega uz dobar sigurnosni profil što je pokazano u kliničkoj 
studiji CheckMate025. Nivolumab u usporedbi s everolimusom produljuje preživljenje kod bolesnika sa mRCC uz povoljni 
sigurnosni profil lijeka. U ovoj analizi smo prikazali rezultate liječenja bolesnika nivolumabom u NPP u Kliničkom bolnič-
kom centru Zagreb tijekom 2016. do 2018. 30% bolesnika ima preživljenje dulje od 30 mjeseci, a 16.6% je imalo kompletni 
odgovor na terapiju.
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INTRODUCTION
After decades of slow progress, the field of 
metastatic renal cancer (mrcc) treatments is now 
evolving at a rapid and unprecedented pace. 
nivolumab is an anti-programmed death-1 (pD-1) 
receptor antibody (novel immune checkpoint in-
hibitor) that prolongs survival in patients with 
metastatic kidney cancer with a good safety pro-
file, as demonstrated in the CheckMate 025 clinical 
randomized phase III trial. The median overall 
survival was 25.0 months with nivolumab and 
19.6 months with everolimus(1). The hazard ratio 
for nivolumab versus everolimus was 0.73 (98.5% 
CI, 0.57 to 0.93; P=0.002). The objective response 
rate was greater with nivolumab than with evero-
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limus (25% vs. 5%) (1). the median progression-
free survival was 4.6 months with nivolumab and 
4.4 months with everolimus grade 3 or 4 treat-
ment-related adverse events occurred in 19% of 
patients receiving nivolumab and in 37% of pa-
tients receiving everolimus; the most common ad-
verse event with nivolumab was fatigue (in 2% of 
patients), with everolimus it was anemia (in 8%) 
(1). esMo and nccn guidelines recommended 
nivolumab as an option in the second-line therapy 
after failure of first-line antiangiogenic therapy 
and if nivolumab was not used as the first-line 
therapy (2,3).
We wished to participate in the nivolumab 
donation program to improve the treatment of our 
patients without financially burdening the Croa-
tian Health insurance fund.
MATERIAL AND METHODS
patients with metastatic kidney cancer 
(mrcc) received tyrosine kinase inhibitors (tKi) 
or temsirolimus as the first-line therapy, and sub-
sequently, they received nivolumab 3 mg/kg npp 
every two weeks from 2016 to 2018. in patients 
who did not have disease progression or grade 3 
and 4 toxicity, nivolumab treatment was contin-
ued, funded by the croatian Health insurance. pa-
tients are regularly monitored every three months 
with ct of the chest, abdomen, and pelvis, with 
bone analysis, laboratory tests (hematology, bio-
chemistry, t4, tsH). the decision about the thera-
py continuation depended on adverse events and 
disease progression. We also respect patients´ 
preference regarding cycle dynamics (cycles with 
occasional breaks in treatment), especially in pa-
tients who previously had one year of nivolumab 
therapy.
RESULTS
We treated 30 patients (22 men and 8 women) 
with mrcc, who initially received tKi therapy 
with the median age at diagnosis of kidney cancer 
60.2 (± 9.79 years). Most patients belonged to inter-
mediate-risk, according to the MsKcc risk group. 
As the first-line treatment, the majority of patients, 
23 out of 30 received sunitinib, 6 out of 30 received 
pazopanib, and 1 out of 30 received temsirolimus. 
nine patients (30%) achieved survival over 30 
months (31 ± 0.95 months) after treatment with 
nivolumab as the second-line therapy. a total of 5 
patients (16.6%) had a complete response to 
nivolumab therapy. grade 2 fatigue, according to 
common toxicity criteria (ctc) version 4, was the 
most common side effect of treatment with 
nivolumab.
DISCUSSION
Nivolumab is the first immune-checkpoint 
inhibitor approved for second-line therapy of 
mrcc after progression on vascular endothelial 
growth factor (Vegf)-tKis (4,5). nivolumab has 
clearly shown the benefit when compared to 
everolimus in second-line mrcc therapy (1,4). 
We observed excellent treatment responses. even 
though the treatment of advanced rcc has 
changed in recent years, longlasting complete re-
missions, although recorded, are exceptional with 
single immunotherapy agents and mrcc remains 
an incurable disease.
Further research is needed to better under-
stand the criteria for selection of patients, to dis-
cover and better characterize potential biomark-
ers, to explore possibilities of to combinational 
therapies and to define optimal sequence of the-
rapies in order to achieve the best outcome for 
 patients.
CONCLUSION
in our limited, single-institution experience, 
nivolumab as a second-line agent, in patients who 
progressed on first-line antiangiogenic therapy, 
achieved favorable efficacy and toxicity profile 
similar to those observed in large clinical trials. 
Our definitive observations are limited due to a 
small number of included patients, and further re-
search is needed to better characterize nivolumab 
efficacy and toxicity for every day clinical practice.
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